Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplantation + pembrolizumab
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intravenous, Rectal
01
Overview
This investigational combination therapy is being evaluated by the M.D. Anderson Cancer Center for the treatment of metastatic colorectal adenocarcinoma and small intestinal adenocarcinoma. The regimen involves the use of Fecal Microbiota Transplantation (FMT) in conjunction with the re-introduction of anti-PD-1 immune checkpoint inhibitors, specifically pembrolizumab or nivolumab. The approach is targeted at patients with deficient mismatch repair (dMMR) tumors who have previously failed or progressed on anti-PD-1 therapy. FMT, which contains healthy bacteria and viruses from donor stool, is used to modulate the gut microbiome, aiming to restore the immune system's sensitivity to checkpoint inhibition and overcome therapeutic resistance. The therapy is administered via colonoscopic transplant or oral capsules, following a gut decontamination protocol using antibiotics such as metronidazole, neomycin, and vancomycin.
- Other names
- fecal microbiota transplantation-M.D. Anderson Cancer Center-colorectal adenocarcinoma-small intestinal adenocarcinomafecal microbiota transplantation + nivolumabFMT + anti-PD-1 therapyFMT + pembrolizumabFMT + nivolumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on fecal microbiota transplantation + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplantation + pembrolizumab.